Xintela AB (XINT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Xintela AB (XINT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8295
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xintela AB (Xintela) is a biomedical company that develops treatment for cartilage damage and brain tumors. The company’s technology includes Xinmark, a patented marker technology developed to identify and select certain types of tumor cells, which can develop into cartilage cells. It also provides analytical test such as XACT (Xintela Assay for Cell Therapy), used for quality assurance of methods and cells. Xintela’s analytical test finds application in research and development activities for stem cell products. It develops therapeutic antibodies, which bind to cancer cells. The company conducts its research in the fields of regenerative medicine and cancer with significance on cartilage damage such as osteoarthritis and brain cancer. Xintela is headquartered in Lund, Sweden.

Xintela AB (XINT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xintela AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Xintela AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Xintela AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Xintela Raises US$0.9 Million In Venture Financing 10
Partnerships 11
CO.DON to Form Joint Venture with Xintela 11
Xintela Enters into Collaboration Agreement with CellSeed 12
Xintela to Enter into Agreement with Co.don 13
Licensing Agreements 14
Xintela Licenses Human Antibody Technology for Cancer Therapy 14
Equity Offering 15
Xintela Raises USD1.1 Million in Private Placement of Shares 15
Xintela Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 16
Xintela Completes Underwriter’s Exercise of Over-Allotment Option of Rights Offering for USD4 Million 17
Xintela AB – Key Competitors 18
Xintela AB – Key Employees 19
Xintela AB – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Strategy And Business Planning 21
Aug 29, 2018: Xintela to spin out oncology business 21
Sep 11, 2017: Xintela building own GMP-facility for stem cell production 22
Corporate Communications 23
Aug 29, 2018: Xintela appoints Sven Kili as Chief Medical Officer 23
Oct 17, 2017: Keld Sondergaard leaves Xintela’s Board of Directors 24
Product News 25
Dec 29, 2017: Xintela licenses human antibody technology for cancer therapy 25
Apr 17, 2018: Xintela develops unique methods in stem cell therapy for the brain and broadens patent portfolio 26
Other Significant Developments 27
Aug 21, 2018: Xintela: Significant progress in development programs 27
Apr 26, 2018: Xintela’s GMP facility is completed and being prepared for production and clinical trials 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Xintela AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xintela AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xintela AB, Deals By Therapy Area, 2012 to YTD 2018 8
Xintela AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Xintela Raises US$0.9 Million In Venture Financing 10
CO.DON to Form Joint Venture with Xintela 11
Xintela Enters into Collaboration Agreement with CellSeed 12
Xintela to Enter into Agreement with Co.don 13
Xintela Licenses Human Antibody Technology for Cancer Therapy 14
Xintela Raises USD1.1 Million in Private Placement of Shares 15
Xintela Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 16
Xintela Completes Underwriter’s Exercise of Over-Allotment Option of Rights Offering for USD4 Million 17
Xintela AB, Key Competitors 18
Xintela AB, Key Employees 19

List of Figures
Xintela AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xintela AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Xintela AB (XINT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ajman Bank (AJMANBANK):企業の財務・戦略的SWOT分析
    Ajman Bank (AJMANBANK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • One Lambda Inc-医療機器分野:企業M&A・提携分析
    Summary One Lambda Inc (One Lambda), a subsidiary of Thermo Fisher Scientific Inc is a medical device company that offers laboratory products. The company develops and distributes histocompatibility typing tests and antibody detection products. Its products include HLA tissue typing trays, HLA testi …
  • Seoul City Gas Co Ltd (017390):企業の財務・戦略的SWOT分析
    Seoul City Gas Co Ltd (017390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Hellenic Petroleum SA (ELPE):石油・ガス:M&Aディール及び事業提携情報
    Summary Hellenic Petroleum S.A. (Hellenic Petroleum) is an integrated oil and gas company. It refines, supplies, and trades oil products, natural gas; and markets fuels in Greece and South-eastern European markets with a network of petrol stations. The company owns and operates vertically integrated …
  • Techno – Agricultural Supplying (TSC):企業の財務・戦略的SWOT分析
    Techno - Agricultural Supplying (TSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • SYSTRA S.A.:企業の戦略・SWOT・財務情報
    SYSTRA S.A. - Strategy, SWOT and Corporate Finance Report Summary SYSTRA S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Asuragen Inc-医療機器分野:企業M&A・提携分析
    Summary Asuragen Inc (Asuragen) is a provider of laboratory medicine solutions. The company offers products which include amplidex, quantidex, and custom reagents. It offers custom and companion diagnostic services which include commercialization, product approval, development, discovery, partnered …
  • SJVN Ltd (SJVN)-エネルギー分野:企業M&A・提携分析
    Summary SJVN Limited (SJVN), formerly Satluj Jal Vidyut Nigam Limited-SJVNL, generates and sells hydroelectric power in India. It was formed as a joint venture between the Government of India (GOI) and the Government of Himachal Pradesh (GOHP). The company also focuses on the designing, planning, de …
  • Etablissementen Franz Colruyt NV (COLR):企業の財務・戦略的SWOT分析
    Etablissementen Franz Colruyt NV (COLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Blue Cross and Blue Shield Association:企業の戦略的SWOT分析
    Blue Cross and Blue Shield Association - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Camaieu:企業の戦略・SWOT・財務情報
    Camaieu - Strategy, SWOT and Corporate Finance Report Summary Camaieu - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • IDEXX Laboratories, Inc.:企業の戦略・SWOT・財務情報
    IDEXX Laboratories, Inc. - Strategy, SWOT and Corporate Finance Report Summary IDEXX Laboratories, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AS Eesti Gaas:企業の戦略的SWOT分析
    AS Eesti Gaas - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Antong Holdings Co., Ltd. (600179):企業の財務・戦略的SWOT分析
    Antong Holdings Co., Ltd. (600179) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Tenaga Nasional Berhad:企業の戦略・SWOT・財務情報
    Tenaga Nasional Berhad - Strategy, SWOT and Corporate Finance Report Summary Tenaga Nasional Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Symphony Ltd:企業の戦略・SWOT・財務分析
    Symphony Ltd - Strategy, SWOT and Corporate Finance Report Summary Symphony Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Main Street America Insurance Company:企業の戦略的SWOT分析
    Main Street America Insurance Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Ernst & Young Global Ltd
    Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report Summary Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Direct Energy Marketing Ltd:電力:M&Aディール及び事業提携情報
    Summary Direct Energy Marketing Ltd (Direct Energy), a subsidiary of Centrica plc, is a provider of energy and energy-related services. The company supplies, transports, and distributes natural gas and electricity. Direct Energy also installs and maintains heating, ventilation and air conditioning ( …
  • Panhandle Oil and Gas Inc (PHX):企業の財務・戦略的SWOT分析
    Panhandle Oil and Gas Inc (PHX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆